Quantitative Concept
Skye Bioscience Abandons Eye Disease Pipeline, Shifts Focus to Obesity Treatment After Phase 2a Trial Failure
Skye Bioscience, eye disease, Phase 2a trial, obesity treatment, stock price, biotech company
Oculis Announces Phase 2 Results for Licaminlimab in Dry Eye Disease, Despite Limited Statistical Significance
Oculis, Licaminlimab, Dry Eye Disease, Phase 2 Results, Statistical Significance
Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign
Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry
Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook
Biopharma, Funding Levels, Federal Interest Rates, PitchBook, Venture Capital
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)
Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome
Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge
Brandon Capital Raises $180M Fund to Boost Australia and New Zealand Biotechs
Brandon Capital, biotechs, Australia, New Zealand, life sciences, venture capital, fund, startups, scale-ups
LGBTQ+ Populations Face Higher Cancer Risk Due to Barriers to Healthcare
LGBTQ+, cancer risk, barriers to healthcare, American Cancer Society, discrimination, minority stress
BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati
Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA